AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

by Barry101 | Apr 11, 2022 | Press Release, Uncategorized

Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park...

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

by Barry101 | Apr 11, 2022 | Press Release, Uncategorized

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term systemic CKM followed...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

by Barry101 | Mar 31, 2022 | Press Release, Uncategorized

– Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications – Company expected to continue advancing oncology-focused...

AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

by Barry101 | Mar 28, 2022 | Press Release, Uncategorized

OCALA, Fla., March 28, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting

by Barry101 | Mar 24, 2022 | Press Release, Uncategorized

OCALA, Fla., March 24, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...